Is Gd-DTPA required for routine cranial MR imaging?

A. D. Elster, D. M. Moody, M. R. Ball, D. W. Laster

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Gadopentate dimeglumine (gadolinium diethylenetriaminepentaacetic acid [DTPA]) was administered prospectively to 500 consecutive children and adults referred for routine cranial magnetic resonance (MR) imaging over a 4-month period. Pre- and postcontrast images were blindly and independently interpreted by two experienced neuroradiologists. Specific criteria were provided to the readers to define objectively when contrast material enhancement (or lack thereof) would be considered 'radiologically helpful'. Contrast-enhancing lesions were observed in 99 cases (20%). In only 15 cases (3%) did Gd-DTPA permit detection of lesions not also apparent on the precontrast studies. Contrast enhancement was considered radiologically helpful in 74 of the 99 cases. Lack of enhancement was considered helpful in 112 of the 500 cases (22%). Factors that may indicate increased usefulness of Gd-DTPA include increased patient age, definite lesions seen at computed tomography or precontrast MR imaging, prior craniotomy for tumor, and clinically documented systemic or central nervous system disease. Gd-DTPA should probably be used routinely for cranial MR imaging in most patients, except, perhaps, children and young adults with normal precontrast images.

Original languageEnglish (US)
Pages (from-to)231-238
Number of pages8
JournalRadiology
Volume173
Issue number1
StatePublished - 1989
Externally publishedYes

Fingerprint

Magnetic Resonance Imaging
Acids
Craniotomy
Central Nervous System Diseases
Gadolinium
Contrast Media
Young Adult
Tomography
Neoplasms

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Elster, A. D., Moody, D. M., Ball, M. R., & Laster, D. W. (1989). Is Gd-DTPA required for routine cranial MR imaging? Radiology, 173(1), 231-238.

Is Gd-DTPA required for routine cranial MR imaging? / Elster, A. D.; Moody, D. M.; Ball, M. R.; Laster, D. W.

In: Radiology, Vol. 173, No. 1, 1989, p. 231-238.

Research output: Contribution to journalArticle

Elster, AD, Moody, DM, Ball, MR & Laster, DW 1989, 'Is Gd-DTPA required for routine cranial MR imaging?', Radiology, vol. 173, no. 1, pp. 231-238.
Elster AD, Moody DM, Ball MR, Laster DW. Is Gd-DTPA required for routine cranial MR imaging? Radiology. 1989;173(1):231-238.
Elster, A. D. ; Moody, D. M. ; Ball, M. R. ; Laster, D. W. / Is Gd-DTPA required for routine cranial MR imaging?. In: Radiology. 1989 ; Vol. 173, No. 1. pp. 231-238.
@article{d1e67a984ef346d39c962847a2ceac06,
title = "Is Gd-DTPA required for routine cranial MR imaging?",
abstract = "Gadopentate dimeglumine (gadolinium diethylenetriaminepentaacetic acid [DTPA]) was administered prospectively to 500 consecutive children and adults referred for routine cranial magnetic resonance (MR) imaging over a 4-month period. Pre- and postcontrast images were blindly and independently interpreted by two experienced neuroradiologists. Specific criteria were provided to the readers to define objectively when contrast material enhancement (or lack thereof) would be considered 'radiologically helpful'. Contrast-enhancing lesions were observed in 99 cases (20{\%}). In only 15 cases (3{\%}) did Gd-DTPA permit detection of lesions not also apparent on the precontrast studies. Contrast enhancement was considered radiologically helpful in 74 of the 99 cases. Lack of enhancement was considered helpful in 112 of the 500 cases (22{\%}). Factors that may indicate increased usefulness of Gd-DTPA include increased patient age, definite lesions seen at computed tomography or precontrast MR imaging, prior craniotomy for tumor, and clinically documented systemic or central nervous system disease. Gd-DTPA should probably be used routinely for cranial MR imaging in most patients, except, perhaps, children and young adults with normal precontrast images.",
author = "Elster, {A. D.} and Moody, {D. M.} and Ball, {M. R.} and Laster, {D. W.}",
year = "1989",
language = "English (US)",
volume = "173",
pages = "231--238",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Is Gd-DTPA required for routine cranial MR imaging?

AU - Elster, A. D.

AU - Moody, D. M.

AU - Ball, M. R.

AU - Laster, D. W.

PY - 1989

Y1 - 1989

N2 - Gadopentate dimeglumine (gadolinium diethylenetriaminepentaacetic acid [DTPA]) was administered prospectively to 500 consecutive children and adults referred for routine cranial magnetic resonance (MR) imaging over a 4-month period. Pre- and postcontrast images were blindly and independently interpreted by two experienced neuroradiologists. Specific criteria were provided to the readers to define objectively when contrast material enhancement (or lack thereof) would be considered 'radiologically helpful'. Contrast-enhancing lesions were observed in 99 cases (20%). In only 15 cases (3%) did Gd-DTPA permit detection of lesions not also apparent on the precontrast studies. Contrast enhancement was considered radiologically helpful in 74 of the 99 cases. Lack of enhancement was considered helpful in 112 of the 500 cases (22%). Factors that may indicate increased usefulness of Gd-DTPA include increased patient age, definite lesions seen at computed tomography or precontrast MR imaging, prior craniotomy for tumor, and clinically documented systemic or central nervous system disease. Gd-DTPA should probably be used routinely for cranial MR imaging in most patients, except, perhaps, children and young adults with normal precontrast images.

AB - Gadopentate dimeglumine (gadolinium diethylenetriaminepentaacetic acid [DTPA]) was administered prospectively to 500 consecutive children and adults referred for routine cranial magnetic resonance (MR) imaging over a 4-month period. Pre- and postcontrast images were blindly and independently interpreted by two experienced neuroradiologists. Specific criteria were provided to the readers to define objectively when contrast material enhancement (or lack thereof) would be considered 'radiologically helpful'. Contrast-enhancing lesions were observed in 99 cases (20%). In only 15 cases (3%) did Gd-DTPA permit detection of lesions not also apparent on the precontrast studies. Contrast enhancement was considered radiologically helpful in 74 of the 99 cases. Lack of enhancement was considered helpful in 112 of the 500 cases (22%). Factors that may indicate increased usefulness of Gd-DTPA include increased patient age, definite lesions seen at computed tomography or precontrast MR imaging, prior craniotomy for tumor, and clinically documented systemic or central nervous system disease. Gd-DTPA should probably be used routinely for cranial MR imaging in most patients, except, perhaps, children and young adults with normal precontrast images.

UR - http://www.scopus.com/inward/record.url?scp=0024454499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024454499&partnerID=8YFLogxK

M3 - Article

C2 - 2781014

AN - SCOPUS:0024454499

VL - 173

SP - 231

EP - 238

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 1

ER -